EWA
MPLT

EverSource Wealth Advisors’s MapLight Therapeutics MPLT Stock Holding History

EverSource Wealth Advisors’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$287 Buy
8
+2
+33% +$58 ﹤0.01% 4210
2026
Q1 		$122 Buy
+6
New +$107 ﹤0.01% 4249

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

EverSource Wealth Advisors's MPLT Position: Q2 2026 in Review

EverSource Wealth Advisors increased its MapLight Therapeutics (MPLT) stake by 33% in Q2 2026, buying an estimated $58 and bringing the position to 8 shares worth $287. The position accounts for ﹤0.01% of the portfolio, ranked #4210.

EverSource Wealth Advisors first reported a position in MPLT in Q1 2026 and has held it in 2 quarters since. 100 funds tracked by Wall St. Rank hold MPLT as of Q2 2026.

  • EverSource Wealth Advisors held 8 shares of MapLight Therapeutics worth $287 as of Q2 2026.
  • EverSource Wealth Advisors bought 2 MapLight Therapeutics shares in Q2 2026, an estimated $58.
  • MapLight Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #4210 holding.
  • EverSource Wealth Advisors first reported a position in MapLight Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 100 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.